| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ITOC2 – 036. A method for developing predictive tests for immunotherapy benefit
|
Heinrich, Roder
|
|
2015
|
51 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 2 |
ITOC2 – 026. A new fusion receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
|
Sebastian, Kobold
|
|
2015
|
51 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 3 |
ITOC2 – 019. An open-label multicenter phase II trial of aviscumine in previously treated patients with unresectable stage IV metastatic melanoma
|
Uwe, Trefzer
|
|
2015
|
51 |
S1 |
p. S7-
1 p.
|
artikel
|
| 4 |
ITOC2 – 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours
|
Bacac, Marina
|
|
2015
|
51 |
S1 |
p. S13-
1 p.
|
artikel
|
| 5 |
ITOC2 – 029. Combination of CTLA4-blockade, depletion of CD25+ cells and active-specific immunotherapy prolongs survival in murine melanoma
|
Julia, Kovács R.
|
|
2015
|
51 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 6 |
ITOC2 – 034. Development of a 3D cell culture model for the investigation of cancer cell/immune cell interactions
|
Stefan, Köck
|
|
2015
|
51 |
S1 |
p. S12-
1 p.
|
artikel
|
| 7 |
ITOC2 – 016. Effective vaccination against melanoma in an animal study: Combination of laser-assisted dermal skin delivery and cross-presenting XCR1+ dermal DCs targeting
|
Dora, Terhorst D.T.
|
|
2015
|
51 |
S1 |
p. S6-
1 p.
|
artikel
|
| 8 |
ITOC2 – 005. Humanized mouse models for preclinical testing of antitumour immune therapy
|
Annika, Wulf-Goldenberg
|
|
2015
|
51 |
S1 |
p. S2-
1 p.
|
artikel
|
| 9 |
ITOC2 – 018. Hyperthermia induced immunogenic cell-death
|
Gabor, Andocs
|
|
2015
|
51 |
S1 |
p. S7-
1 p.
|
artikel
|
| 10 |
ITOC2 – 011. Identification of second-generation potent and selective inhibitors of indoleamine-2,3-dioxygenase-1 (IDO1) for the treatment of cancer
|
Juan, Jaen C.
|
|
2015
|
51 |
S1 |
p. S4-
1 p.
|
artikel
|
| 11 |
ITOC2 – 030. Identification of the neoantigen Ndufs1-V491A for investigations on immunotherapies in murine tumour models
|
Anja, Schumacher
|
|
2015
|
51 |
S1 |
p. S11-
1 p.
|
artikel
|
| 12 |
ITOC2 – 004. Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in situ in FFPE tissue sections
|
James, Mansfield R.
|
|
2015
|
51 |
S1 |
p. S2-
1 p.
|
artikel
|
| 13 |
ITOC2 – 014. Immunomodulation of blasts in AML-patients (AML-pts) with clinically approved response modifiers to improve antileukemic T-cell reactivity: An ex vivo simulation of the clinical
|
Helga, Schmetzer
|
|
2015
|
51 |
S1 |
p. S5-
1 p.
|
artikel
|
| 14 |
ITOC2 – 031. Immunomodulatory characteristics of Resminostat, a novel HDAC inhibitor in phase II clinical development
|
Svetlana, Hamm
|
|
2015
|
51 |
S1 |
p. S11-
1 p.
|
artikel
|
| 15 |
ITOC2 – 002. Immunosuppressive microenvironment in pancreatic adenocarcinoma
|
Svetlana, Karakhanova
|
|
2015
|
51 |
S1 |
p. S1-
1 p.
|
artikel
|
| 16 |
ITOC2 – 033. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma
|
Svetlana, Karakhanova
|
|
2015
|
51 |
S1 |
p. S12-
1 p.
|
artikel
|
| 17 |
ITOC2 – 001. Influence of tumour cell – Fibroblast co-culture on monocyte differentiation and tumour growth in pancreatic cancer
|
Janina, Findeis J.F.
|
|
2015
|
51 |
S1 |
p. S1-
1 p.
|
artikel
|
| 18 |
ITOC2 – 023. Integrated computational pipeline for development of personalised melanoma vaccine
|
Tanushree, Jaitly
|
|
2015
|
51 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 19 |
ITOC2 – 013. In vitro kynurenine modulation by novel dual-acting and selective TDO and IDO inhibitors
|
Alan, Wise
|
|
2015
|
51 |
S1 |
p. S5-
1 p.
|
artikel
|
| 20 |
ITOC2 – 008. Melanoma differentiation-associated protein 5 (MDA5)-based tumour immunotherapy reprograms M2/G2-polarised myeloid-derived suppressor cells (MDSCs)
|
Sabrina, Kirchleitner V.
|
|
2015
|
51 |
S1 |
p. S3-
1 p.
|
artikel
|
| 21 |
ITOC2 – 012. Neoadjuvant immune checkpoint blockade for pancreatic cancer prevents local tumour recurrence through tissue resident antitumoural CD8+ CD103+ T cells
|
Jennifer, Brooks
|
|
2015
|
51 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 22 |
ITOC2 – 006. Notch triggers myeloid reprogramming in murine pancreatic cancer
|
Florian, Neff
|
|
2015
|
51 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 23 |
ITOC2 – 032. Optimising active-specific immunotherapy in lymphodepleted mice with subcutaneous melanoma
|
Peter, Rose
|
|
2015
|
51 |
S1 |
p. S11-
1 p.
|
artikel
|
| 24 |
ITOC2 – 017. Prolonged survival for patients with recurrent glioblastoma multiforme who are treated with tumour lysate-pulsed autologous dendritic cells
|
Marnix, Bosch L.
|
|
2015
|
51 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 25 |
ITOC2 – 027. Redirecting adenovirus-specific T cells by a tumour-specific T cell receptor for therapy of hepatocellular carcinoma
|
Cristina, Ureche I.
|
|
2015
|
51 |
S1 |
p. S10-
1 p.
|
artikel
|
| 26 |
ITOC2 – 038. Role of exosomes in immune suppression
|
Huber, Veronica
|
|
2015
|
51 |
S1 |
p. S13-
1 p.
|
artikel
|
| 27 |
ITOC2 – 009. Role of signal transduction and microRNAs on the immunogenicity of melanoma cells
|
Stefanie, Meyer
|
|
2015
|
51 |
S1 |
p. S3-
1 p.
|
artikel
|
| 28 |
ITOC2 – 024. Selective lysis of biphenotypic leukaemia cells is mediated by dual-targeting triplebody 33-3-19 treatment
|
Claudia, Roskopf C.
|
|
2015
|
51 |
S1 |
p. S9-
1 p.
|
artikel
|
| 29 |
ITOC2 – 003. Store-operated calcium signaling in EGF-mediated COX-2 inflammatory gene activation in cancer cells
|
Yuan, Wang Jaw
|
|
2015
|
51 |
S1 |
p. S2-
1 p.
|
artikel
|
| 30 |
ITOC2 – 035. The immunotherapeutic TLR-9 agonist MGN1703 – Pharmacokinetic and pharmacodynamic data from healthy volunteers and cancer patients
|
Manuel, Schmidt
|
|
2015
|
51 |
S1 |
p. S12-
1 p.
|
artikel
|
| 31 |
ITOC2 – 021. The melanoma immune-peptidome for T-cell-based anti-tumour immunotherapies
|
Michal, Bassani-Sternberg
|
|
2015
|
51 |
S1 |
p. S8-
1 p.
|
artikel
|
| 32 |
ITOC2 – 015. Therapy of hepatocellular carcinoma (HCC) with immunostimulatory RNA activating RIG-I
|
Laura, Posselt
|
|
2015
|
51 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 33 |
ITOC2 – 025. Transduction with C-C-chemokine receptor type 4 (CCR4) enhances tumour-specific migration of adoptively transferred T cells in a model of pancreatic cancer
|
Moritz, Rapp
|
|
2015
|
51 |
S1 |
p. S9-
1 p.
|
artikel
|
| 34 |
ITOC2 – 028. Transgenic antigen-specific, allogeneic HLA-A∗0201-restricted cytotoxic T cells recogniae tumour-associated target antigen STEAP1 with high specificity
|
David, Schirmer
|
|
2015
|
51 |
S1 |
p. S10-
1 p.
|
artikel
|
| 35 |
ITOC2 – 007. Two immune faces of pancreatic adenocarcinoma: Impact of immunosuppression
|
Alexandr, Bazhin V.
|
|
2015
|
51 |
S1 |
p. S3-
1 p.
|
artikel
|
| 36 |
ITOC2 – 022. Vaccination with next-generation dendritic cells for AML postremission therapy induces antigen-specific T cell responses
|
Frauke, Schnorfeil
|
|
2015
|
51 |
S1 |
p. S8-
1 p.
|
artikel
|
| 37 |
ITOC2 – 020. VGX-3100 Immunotherapy for CIN2/3 Induces regression of cervical lesions and viral clearance (Phase II study): Implications for treatment of HPV associated cancers
|
Niranjan, Sardesai
|
|
2015
|
51 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 38 |
ITOC2 – 010. Virotherapy overcomes tumour resistance to PD1-immunotherapy by broad mutanome-directed T cell responses
|
Norman, Woller
|
|
2015
|
51 |
S1 |
p. S4-
1 p.
|
artikel
|
Tijdschrift beschrijving